

Predicting Which Children with Juvenile Idiopathic Arthritis Will Have a Severe Disease Course: Results from the ReACCh-Out Cohort

Jaime Guzman, Andrew Henrey, Thomas Loughin, Roberta A. Berard, Natalie J. Shiff, Roman Jurencak, Susanne M. Benseler, and Lori B. Tucker, on behalf of the ReACCh-Out Investigators

ABSTRACT. Objective. We studied an inception cohort of children with juvenile idiopathic arthritis (JIA) to (1) identify distinct disease courses based on changes over 5 years in 5 variables prioritized by patients, parents, and clinicians; and (2) estimate the probability of a severe disease course for each child at diagnosis.

Methods. Assessments of quality of life, pain, medication requirements, patient-reported side effects, and active joint counts were scheduled at 0, 6, 12, 18, 24, 36, 48, and 60 months. Patients who attended at least 6 assessments were included. Multivariable cluster analysis, r^2 , and silhouette statistics were used to identify distinct disease courses. One hundred candidate prediction models were developed in random samples of 75% of the cohort; their reliability and accuracy were tested in the 25% not used in their development.

Results. Four distinct courses were identified in 609 subjects. They differed in prioritized variables, disability scores, and probabilities of attaining inactive disease and remission. We named them Mild (43.8% of children), Moderate (35.6%), Severe Controlled (9%), and Severe Persisting (11.5%). A logistic regression model using JIA category, active joint count, and pattern of joint involvement at enrollment best predicted a severe disease course (Controlled + Persisting, c-index = 0.87); 91% of children in the highest decile of risk actually experienced a severe disease course, compared to 5% of those in the lowest decile.

Conclusion. Children in this JIA cohort followed 1 of 4 disease courses and the probability of a severe disease course could be estimated with information available at diagnosis. (First Release December 15 2016; J Rheumatol 2017;44:230–40; doi:10.3899/jrheum.160197)

Key Indexing Terms:

JUVENILE ARTHRITIS
PROGNOSIS

PREDICTION

RISK STRATIFICATION
TREATMENT

Shared decision making of physicians and parents is essential to ensure optimal outcomes for children with juvenile idiopathic arthritis (JIA). Sharing decisions requires effective communication of the expected disease course and the risks associated with treatment. The course of JIA is hard to explain to patients and their parents. Previous studies have concentrated on the number of affected joints¹ or episodes of disease activity² over time, and on predicting remission,

functional status, or radiological evidence of joint damage at variable times after diagnosis^{3,4,5}.

In a previous study we asked adolescents with JIA, parents of children with JIA, and clinicians who care for children with JIA what was most important to them in describing the clinical course of the disease, and what terms should be used to communicate disease course⁶. Five variables were chosen: participant-defined quality of life, pain, medication require-

From the British Columbia Children's Hospital and the University of British Columbia, Vancouver; Simon Fraser University, Burnaby, British Columbia; the Alberta Children's Hospital and University of Calgary, Calgary, Alberta; London Health Sciences Centre and Western University, London; the Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, Canada; the Shands Children's Hospital and University of Florida, Gainesville, Florida, USA.

Funded by a grant from the Canadian Initiative for Outcomes in Rheumatology Care, Canadian Rheumatology Association. The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh-Out) cohort was funded by a New Emerging Team research grant from the Canadian Institutes of Health Research. Dr. Guzman was funded by a Clinical Investigator Award from the Child and Family Research Institute, Vancouver, British Columbia, Canada.

J. Guzman, MD, MSc, British Columbia Children's Hospital and the University of British Columbia; A. Henrey, PhD, Simon Fraser University; T. Loughin, PhD, Professor, Simon Fraser University; R.A. Berard, MD, MSc, London Health Sciences Centre and Western University; N.J. Shiff, MD, MSc, Shands Children's Hospital and University of Florida; R. Jurencak, MD, Children's Hospital of Eastern Ontario and University of Ottawa; S.M. Benseler, MD, PhD, Alberta Children's Hospital and University of Calgary; L.B. Tucker, MD, British Columbia Children's Hospital and the University of British Columbia.

Address reprint requests to Dr. J. Guzman, Division of Pediatric Rheumatology, BC Children's Hospital, 4500 Oak St., Suite K4-122, Vancouver, British Columbia V6H 3N1, Canada. E-mail: jguzman@cw.bc.ca

Accepted for publication October 25, 2016.

ments, medication side effects, and the number of active joints. Plain descriptive terms that conveyed the overall severity of the disease course were preferred.

In our current study we used data from the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort to (1) describe the clinical course of JIA based on changes in these 5 variables during the 5 years after diagnosis, and (2) develop a method to estimate the probability that an individual child will follow a severe disease course, using information available at diagnosis.

MATERIALS AND METHODS

Patients. From 2005 to 2010, the ReACCh-Out study recruited consecutive patients newly diagnosed with JIA at 16 pediatric rheumatology centers^{7,8}. Study visits were scheduled at 0, 6, 12, 18, 24, 36, 48, and 60 months after enrollment to collect demographic and clinical information, juvenile arthritis core variables⁹, medications, and quality-of-life measures^{10,11}. We included subjects who attended at least 6 of the 8 study visits by May 30, 2012, and had at least 1 value recorded for each of the 5 variables detailed below. This study was reviewed and approved by the University of British Columbia Children's and Women's Health Centre Research Ethics Board (number H14-01784).

Variables. Participant-defined quality of life was the answer of the child to the following question from the Quality of My Life Questionnaire¹¹: "Considering my health, my life is..." from 0 = the worst, to 10 = the best. The child made a mark in a horizontal 10-cm visual analog scale (VAS), assisted by the parent as needed.

Pain during the past week was marked by the child or parents (depending on the child's maturity) in a 10-cm horizontal VAS from 0 = no pain, to 10 = worst pain imaginable¹⁰.

Active joint count was the number of joints that were swollen or showed painful limitation of movement when examined by a pediatric rheumatologist (from 0 to 71)¹².

Medication requirements and medication side effects are top priorities for patients, parents, and clinicians⁶, but there are no validated scales to measure these constructs in JIA. The authors developed draft scales based on data available in the ReACCh-Out cohort and convened focus groups of youth with JIA (n = 3), parents of children with JIA (n = 3), and clinicians (2 pediatric rheumatologists, 1 nurse) to evaluate them¹³. The scales were modified according to the feedback received, for use in our study (see Detail of statistical methods, Supplementary Material, Detail of Scales, available with the online version of this article).

Each current antirheumatic medication received at each visit was given a weight, and weights were added to obtain a medication requirements score: corticosteroid joint injection = 1, nonsteroidal antiinflammatory drugs = 1.5, systemic corticosteroid = 3, single disease-modifying antirheumatic drug (DMARD) = 3, multiple DMARD = 5, biologic = 8.

Ten symptoms reported by the patients/parents in the Juvenile Arthritis Quality of Life Questionnaire (JAQQ)¹⁰ as due to arthritis or its treatment were selected by the authors as possible side effects. The frequency of these symptoms was summarized into a 0-to-10 medication side effects scale, from 0 = no side effects, to 6 = 2 side effects occurring 50% or more of the time, and 10 = side effect resulting in death or disability.

Description of clinical course. Our statistical analyses and treatment of missing data are described in full in the Supplementary Material (available with the online version of this article). We summarize the important features here. Missing values for the child's pain were imputed first, using linear regression based on the parent's guess. Other missing values were imputed next. We tested several imputation methods by purposefully deleting values in patients with no missing values and selected the method that best approximated the deleted values; it was a type of regression imputation^{14,15,16}.

After imputation, we used multivariable clustering to group subjects according to their degree of similarity in the 5 variables over 5 years, irrespective of other characteristics. We tried K-means, K-medoids, agglomerative clustering, and divisive clustering^{17,18,19}. Silhouette coefficients and r^2 statistics were compared within each method to measure the relative homogeneity of clusters in relation to others and help select the most appropriate number of clusters¹⁹. We then used silhouette coefficients to help select the best clustering method and the adjusted Rand index to assess stability of the clustering²⁰. We used descriptive statistics and chi-square and Kruskal-Wallis tests to highlight differences across clusters and then assessed their perceived clinical utility. We wanted to determine whether the clusters reflected clinicians' experiences of the course of JIA, and whether the clusters would be easily understood by patients and parents.

After reviewing clustering results, we conducted posthoc analyses to assess whether children with a severe persisting disease course were grouped that way because of an overlying chronic pain syndrome rather than persisting disease activity.

Prediction of a severe disease course. We ordered the clusters (disease courses) according to clinically perceived severity and explored different targets for prediction, e.g., predicting only the most severe course or the 2 most severe courses, etc. We considered explanatory variables (predictors) associated with disease outcomes in previous studies^{3,4,5} and gave preference to variables easily accessible at diagnosis. Logistic regression was used to screen explanatory variables using a modified version of backward elimination. "Full" models with all 52 explanatory variables were fit to each response outcome and the 28 variables with the greatest effects on prediction ability were retained.

We tried 5 binary classification methods: logistic regression, classification tree, random forest, neural networks, and k-nearest neighbor¹⁸, and different combinations of predictors. Subjects were split 75%/25% into "training" and "test" sets. Models were developed in the training set and their predictive ability was measured in the test set¹⁸ using 3 metrics: c-index, a maximum likelihood statistic, and a Pearson statistic based on optimal 3-group risk stratification. Higher values indicate better predictive ability. The process was repeated 50 times for each of 100 candidate models with random selection of the 75% and 25% subsets to assess model stability and compute 95% CI for the 3 metrics. The best model was refit to the full dataset to estimate the final c-index.

Ideally, variable selection and model comparison could be automated in a single round of data splits instead of using 2 separate rounds of splitting for each step. However, variable selection required some judgment and it was easier to implement in 2 steps. Sample-size considerations prevented us from using the 3-way split into training/validation/test samples that is sometimes recommended¹⁸. Our multiple 2-way splits allowed assessment of the stability of our performance metrics and served as a very good substitute.

RESULTS

Patients. Between January 2005 and December 2010, the ReACCh-Out study recruited 1497 children with JIA. As of May 30, 2012, 640 subjects had attended at least 6 study visits, of which 609 provided enough data (Figure 1, Table 1). Compared to excluded subjects, the included subjects were younger (median of 8.4 yrs vs 10.4), had a shorter time from onset to diagnosis (3.7 vs 4.6 mos), and a more severe disease at enrollment [physician's global assessment (PGA) 2.8 vs 2.4 cm, 2 vs 1 active joints]. Polyarthritis and systemic JIA formed a larger proportion of included subjects ($p = 0.05$; chi-square test; Supplementary Table 1, available with the online version of this article).

Physician-reported data were available for > 95% of the 4144 study visits attended by these 609 patients, and




Figure 1. Participant flow chart and patient eligibility. Because a substantial period of observation is essential to describe disease course, we chose to include in this study only patients who had attended at least 6 of 8 possible study visits. The numbers at the bottom of the chart are the numbers of subjects attending each study visit at 6, 12, 18, 24, 36, 48, and 60 months after enrollment. JIA: juvenile idiopathic arthritis.

patient-reported data for 82%-85% of the visits. Missing data at enrollment are reported in Table 1 and missing data at each subsequent visit are reported in Supplementary Table 2, available with the online version of this article. Our minimum requirement was 1 value for each of the 5 prioritized variables (5/40 possible values), but 99% of included subjects had at least 20 valid data points.

Description of clinical course. The values of silhouette coefficients, r^2 statistics, and adjusted Rand index were best, and very similar, for the K-means 4-cluster and 5-cluster models. Based on examination of values of the 5 variables across clusters and discussions among the investigators, we chose the 4-cluster model because it was simpler, easier to convey to families, and more clinically meaningful.

Figure 2 presents lay-language descriptions for the 4 disease courses; Figure 3 presents Kaplan-Meier curves for attaining inactive disease and remission without medications, and flare-free survival for each course. Supplementary Figure

1 (available with the online version of this article) shows mean values and 95% CI for prioritized variables, disability scores²¹, juvenile arthritis disease activity scores²², sedimentation rate, PGA, and parent's global assessments.

A mild disease course ($n = 267$, 43.8%, Figure 2) was characterized by minimal effect on quality of life throughout the 5 years after diagnosis. There was mild initial pain and disability that were quickly controlled. Children in this group had the lowest medication requirements and patient-reported medication side effects, and the greatest chance of attaining inactive disease and remission without medications, with the lowest chance of flares (Figure 3).

A moderate disease course ($n = 217$, 35.6%) was characterized by mild to moderate initial effect on quality of life, pain, and disability, with subsequent improvement. Children in this group had moderate treatment requirements and moderate side effects. Compared to the mild course, it took longer to attain inactive disease and remission without medications, with a higher probability of flares.

Children with a severe controlled disease course ($n = 55$, 9.0%) had levels of quality of life and pain similar to the moderate course, but very high active joint counts at presentation, and required intensive treatment. Levels of disability and PGA scores at presentation were high, but decreased quickly. The probabilities of attaining inactive disease and remission without medications were lower than for children in the mild and moderate disease courses.

Children with a severe persistent disease course ($n = 70$, 11.5%) experienced a moderate effect on their quality of life and persistent pain and disability, even though active joint counts were only moderate at presentation. These children were treated as intensively as those in the severe controlled course, but the effect on quality of life and pain remained problematic. They experienced the most side effects. The probabilities of attaining inactive disease and remission without medications were similar to those of the children with the severe controlled course.

Posthoc analyses showed that relative to subjects in the severe controlled disease course, the group of children with a severe persistent course (1) had similar probabilities of attaining inactive disease; (2) had a comparable proportion of subjects with at least 1 active joint at subsequent visits; (3) had comparable frequency of involvement of neck, wrist, hip, and ankle joints; (4) had a weaker overall correlation of pain intensity and active joint count (Spearman correlation of 0.30 vs 0.46); and (5) showed no differential effect on the Psychosocial and Symptoms domains of the JAQQ (see Posthoc analyses, Supplementary Material, available with the online version of this article).

As expected, children who followed an oligoarthritis extended course were more often classified as moderate or severe, relative to children who followed an oligoarthritis persistent course (data not shown).

As a sensitivity analysis, we repeated clustering in

Table 1. Baseline characteristics of children in each of the 4 juvenile idiopathic arthritis (JIA) disease course groups. Numbers are median and (25th, 75th centiles), unless otherwise specified. Median scores for patient-reported outcomes are after imputation of missing values.

Characteristics	Mild, n = 267	Moderate, n = 217	Severe Controlled, n = 55	Severe Persistent, n = 70	p*	All Subjects, n = 609	Subjects Missing Data (%) **
Age at diagnosis, yrs	7.5 (3.2, 7.5)	7.6 (2.8, 11.6)	10.9 (5.5, 12.8)	11.4 (7.3, 13.1)	0.0001	8.4 (3.4, 11.9)	7 (1.1)
Female, n (%)	171 (64.0)	154 (71.3)	42 (76.4)	46 (65.7)	0.18	413 (67.9)	1 (0.2)
JADAS3	4.7 (2.4, 8.2)	9.7 (5.3, 14.8)	20.1 (16.8, 22.8)	12.3 (7.8, 18.8)	0.0001	7.9 (3.9, 14.3)	84 (13.8)
JIA category (column %, row %)					< 0.001		0 (0)
Oligoarthritis	155 (58.0, 69.5)	59 (27.2, 26.5)	1 (1.8, 0.4)	8 (11.4, 3.6)		223 (36.6, 100)	
RF-negative polyarthritis	28 (10.5, 21.7)	57 (26.3, 44.2)	27 (49.1, 20.9)	17 (24.3, 13.2)		129 (21.2, 100)	
Enthesitis-related	31 (11.6, 38.3)	26 (12.0, 32.1)	7 (12.7, 8.6)	17 (24.3, 21.0)		81 (13.3, 100)	
Systemic	12 (4.5, 25.5)	25 (11.5, 53.2)	4 (7.3, 8.5)	6 (8.6, 12.8)		47 (7.7, 100)	
Psoriatic	14 (5.2, 38.9)	18 (8.3, 50.0)	1 (1.8, 2.8)	3 (4.3, 8.3)		36 (5.9, 100)	
RF-positive polyarthritis	1 (0.4, 3.8)	5 (2.3, 19.2)	13 (23.6, 50.0)	7 (10.0, 26.9)		26 (4.3, 100)	
Undifferentiated	26 (9.7, 38.8)	27 (12.4, 40.3)	2 (3.6, 3.0)	12 (17.1, 17.9)		67 (11.0, 100)	
Active joints (%)							3 (0.5)
Cervical spine	3 (1.1)	5 (2.3)	14 (25.4)	7 (10.0)	< 0.001	29 (4.8)	
Wrist	31 (11.6)	66 (30.4)	51 (92.7)	30 (42.9)	< 0.001	178 (29.2)	
Finger joints	48 (18.0)	74 (34.1)	53 (96.4)	33 (47.1)	< 0.001	208 (34.1)	
Hip	10 (3.7)	24 (11.1)	21 (38.2)	14 (20.0)	< 0.001	69 (11.3)	
Ankle	59 (22.1)	81 (37.3)	46 (83.6)	32 (45.7)	< 0.001	218 (35.8)	
Monoarthritis (%)	96 (36.0)	40 (18.4)	0	8 (11.4)	< 0.001	144 (23.6)	3 (0.5)
Symmetric (%)	70 (26.2)	106 (48.8)	55 (100)	42 (60)	< 0.001	273 (44.8)	3 (0.5)
Enthesitis (%)	22 (8.2)	15 (6.9)	6 (10.9)	14 (20.0)	0.01	8.9	5 (0.8)
Laboratory							
ANA-positive	136 (50.9)	97 (44.7)	24 (43.6)	30 (42.9)	0.392	287 (47.1)	57 (9.4)
B27-positive	25 (9.4)	21 (9.7)	6 (10.9)	12 (17.1)	0.285	64 (10.5)	372 (61)
RF-positive ***	6 (2.2)	15 (6.9)	14 (25.4)	10 (14.3)	< 0.001	45 (7.4)	87 (14.3)
Hemoglobin, g/l	122 (114, 130)	120 (111, 128)	120 (114, 131)	120 (114, 131)	0.168		29 (4.8)
Sedimentation rate, mm/h	20 (9, 34)	23 (11, 40)	20 (9, 49)	21 (9, 41)	0.212	20 (9, 38)	57 (9.4)
Patient/parent report							84 (13.8)
Pain, cm	1.6 (0.5, 3.0)	3.3 (1.6, 5.7)	4.0 (2.1, 6.7)	4.9 (2.7, 6.7)	0.0001	2.7 (0.7, 5.5)	
Quality of My Life Score							
Questionnaire	8.8 (7.5, 9.7)	7.4 (5, 8.9)	7.3 (4.5, 8.6)	4.5 (3.2, 5.9)	0.0001	8 (5.2, 9.5)	
Parent global, cm	0.8 (0.1, 1.8)	2.3 (1.0, 4.4)	3.0 (1.3, 5.5)	3.8 (2.0, 5.4)	0.0001	1.6 (0.4, 4)	
JAQQ score	2.2 (1.6, 2.8)	3.1 (2.2, 4.1)	4.1 (3.0, 5.0)	3.7 (2.7, 4.7)	0.0001	2.7 (1.9, 3.9)	
CHAQ score	0.2 (0, 0.5)	0.5 (0.2, 1.0)	1.0 (0.3, 1.4)	0.8 (0.2, 1.4)	0.0001	0.4 (0.1, 0.9)	
Physician report							3 (0.5)
PGA, cm	1.8 (0.8, 3.4)	3.0 (1.7, 5.4)	6.7 (5.6, 7.9)	4.0 (1.6, 6.2)	0.0001	2.8 (1.1, 5.3)	
Active-joint count	1 (1, 2)	3 (1, 6)	27 (20, 36)	5 (1, 13)	0.0001	2 (1, 6)	
Limited-joint count	1 (0, 2)	2 (0, 4)	10 (3, 19)	2 (0, 5)	0.0001	1 (0, 3)	

* Probability that the difference observed across the 4 clusters is due to chance alone calculated with chi-square test for proportions and with Kruskal-Wallis test for medians. For JIA categories, a single chi-square test with 7 levels/categories was used. ** No. and proportion of subjects with missing data at enrollment. Laboratory testing was done only when clinically indicated and some laboratory tests may have been done at later visits. *** A positive test for rheumatoid factor (RF). This is different from RF-positive polyarthritis, because that JIA category requires involvement of 5 or more joints and 2 positive tests for RF at least 3 months apart. JADAS3: 3-variable Juvenile Arthritis Disease Activity Score (the sum of physician's global assessment, parent's global assessment, and up to 10 active joints); ANA: antinuclear antibodies; B27: HLA-B27 was present; JAQQ: Juvenile Arthritis Quality of Life Questionnaire; CHAQ: Childhood Health Assessment Questionnaire; PGA: physician's global assessment of disease activity.

children with complete data. The results suggested our data imputation was not a source of bias on the clustering of subjects. Supplementary Figure 2 (available with the online version of this article) describes how the above disease courses relate to clusters based on juvenile arthritis core variables and to the alternative 5-cluster option.

Prediction of a severe disease course. Table 1 reports baseline characteristics of subjects in each disease course; Figure 4

shows the performance of the best prediction model; and Table 2 compares it with other candidate models.

The best performing model targeted severe controlled and severe persisting courses combined and was derived using logistic regression; 91% of children assigned to the highest decile of risk by this model actually had a severe course, compared to 5% of those assigned to the lowest decile. If instead of deciles of risk, the model was used to assign low,

Table 2. Proportion of children with a severe disease course (severe controlled and severe persisting combined) in the test data across 50 re-samples, according to their decile of risk. Model 1 was selected as the preferred model. The last column reports results if JIA category assigned by the physician at diagnosis was to be used on its own to predict disease course.

Decile of Risk*	(1) Logistic Regression	(2) Random Forest	(3) K-nearest Neighbor	(4) Neural Network	(5) JIA Category Alone
First (lowest risk)	0.05	0.04	0.16	0.11	0.05
Second	0.03	0.03	0.13	0.10	0.04
Third	0.05	0.05	0.05	0.09	0.06
Fourth	0.07	0.06	0.15	0.10	0.07
Fifth	0.09	0.10	0.11	0.11	0.21
Sixth	0.10	0.13	0.17	0.10	0.32
Seventh	0.14	0.12	0.23	0.11	0.30
Eight	0.21	0.22	0.28	0.22	0.34
Ninth	0.43	0.45	0.29	0.41	0.36
Tenth (highest risk)	0.91	0.88	0.51	0.74	0.37
C-index**	0.85 (0.80, 0.90)	0.85 (0.82, 0.88)	0.67 (0.59, 0.75)	0.75 (0.71, 0.79)	0.71 (0.65, 0.79)
Maximum** likelihood	-51 (-43, -59)	-58 (-49, -66)	-81 (-61, -100)	-107 (-99, -116)	-69 (-60, -77)
Pearson statistic**	47 (34, 61)	45 (37, 53)	12 (3, 20)	26 (18, 33)	13 (7, 19)

* Because the overall frequency of a severe disease course in the cohort was 20.5%, a method in which all deciles of risk had observed frequencies close to 20% has no predictive value, while a method in which deciles 1 to 8 had a frequency of 0% and deciles 9 and 10 had a frequency of 100% would be perfect.

** Numbers are the mean of 50 re-samples and (95% CI). The c-index of 0.85 for Model 1 reported in this table is the mean of 50 re-samples. When the final logistic model was refit to all the data the c-index was 0.87. JIA: juvenile idiopathic arthritis.

moderate, and high risk, this model assigned 436 subjects (71.5%) to a low-risk group with < 20% probability of a severe disease course, 100 subjects (16.4%) to a moderate-risk group with a 20% to 60% probability, and 73 subjects (12.0%) to a high-risk group with > 60% probability.

The signs of the coefficients in the final model shown in Figure 4 may not reflect the direction of the associations in Table 1, but they are correct in the context of the full model. The model was better at predicting the severe controlled course than the severe persisting course, but offered the best performance to predict them together. This final model had an in-sample c-index of 0.87, comparable to values computed on the data splits (mean c-index 0.85). Despite its apparent complexity, the necessary calculations can be handled by any modern smart phone; an online calculator can be found here: <https://shiny.rcg.sfu.ca/jia-sdcc/>. A model developed using random forest methods had similar performance statistics (Table 2). Models predicting the severe persisting course directly were not as robust and often missed severe controlled cases (Supplementary Figure 3, available with the online version of this article). Supplementary Tables 3 and 4 report associations of predictor variables with a severe disease course.

To assess the potential effect of missing data imputation on our prediction model, we conducted a sensitivity analysis including only subjects who had complete data for the predictor variables at enrollment. There were few missing data values for predictors at enrollment and the probabilities of a severe disease course calculated using the model derived from the complete dataset were very similar to those derived from the model based on the imputed dataset (see Supplementary Material, Detail of Statistical Methods, available with the online version of this article).

DISCUSSION

Motivated by the importance of shared decision making by physicians and parents, we undertook to describe the course of JIA using 5 variables prioritized by patients, parents, and clinicians⁶. We found that many children followed a mild disease course (43.8% of children) with minimal disease effect and minimal treatment requirements. About one-third of children (35.6%) followed a moderate course with initial mild to moderate pain and effect on quality of life that subsequently stabilized. There were 2 expressions of a severe disease course: a severe controlled course (9%) that presented with many active joints and improved with intensive treatment; and a severe persisting course that presented with some active joints but had persistent moderate pain and effect on quality of life despite treatment (11.5%).

We chose disease course names that were simple and informative for patients and parents. They are relative to each other, because there is no accepted definition of severe JIA or absolute yardstick to measure severity. Children in these 4 groups also differed in disability scores, PGA, and parent global assessments, and probabilities of attaining inactive disease and disease remission during the 5 years after diagnosis. We found little evidence that a chronic pain syndrome, rather than persistent disease activity, was the main reason for a severe persisting disease course.

We then set out to develop a system to estimate the probability of a severe disease course at diagnosis for each patient. A logistic regression model targeted at severe controlled and severe persisting courses together outperformed other candidate models and had a c-index of 0.87. The c-index varies from 0 to 1, where 0.5 corresponds to chance alone and 1.0 is perfect prediction. Values above 0.7 are considered helpful. For reference, the widely used Framingham




Figure 2. Lay language descriptions of the 4 juvenile idiopathic arthritis (JIA) disease course groups: (A) Mild, (B) Moderate, (C) Severe Controlled, and (D) Severe Persisting. The charts show median values for each variable over the 5 years after diagnosis. Effect on quality of life was calculated as 10 minus the Quality of My Life score. Median active joint counts above 10 were charted as 10. A. The most common course, seen in about 45% of children with JIA. The disease responds quickly to simple treatments, but it comes back once or twice during the first 5 years after diagnosis, requiring re-initiation of treatment. Each flare involves a few swollen joints and mild pain, with slight effect on the child's quality of life. Between flares, the child has essentially a normal life. B. The second most common course, seen in about 35% of children with JIA. There is some initial effect on quality of life and mild to moderate pain, with several swollen joints. With relatively simple treatments the disease is eventually controlled and the condition is stable. There may be flares. C. This course is rare, seen in about 10% of children with JIA. There is some initial effect on quality of life and moderate pain levels with many swollen joints at the beginning. After receiving aggressive treatment, with some side effects, the disease is controlled, pain decreases, and the condition stabilizes. D. This rare course is seen in about 10% of children with JIA. Many treatments are tried over the first 5 years after diagnosis and the child experiences frequent side effects, making it difficult to continue the treatment. Despite treatment, there are ongoing problems with some swollen joints and persistent pain. The child's quality of life is moderately affected.




Figure 3. Kaplan–Meier curves for the probability of attaining inactive disease (A) and remission without medications (B) for the 4 juvenile idiopathic arthritis disease courses. Also shown are Kaplan–Meier curves for flare-free survival after attaining inactive disease (C). All Kaplan–Meier curves refer to the first occurrence of the event of interest; subsequent occurrences in the same subject are not considered. In all 3 panels the curves are statistically different, with a $p < 0.0001$ by log-rank test. Inactive disease was defined as an active joint count of 0, absence of systemic manifestations in those with systemic arthritis, absence of enthesitis in those with enthesitis-related arthritis or psoriatic arthritis, absence of uveitis and a physician’s global assessment < 10 mm. This definition was based on that of Wallace, *et al*, with modifications². Remission without medications was defined as at least 12 months with inactive disease after discontinuation of all antirheumatic treatments. Flare was defined as any recurrence of disease manifestations after attaining inactive disease.

A. The probability of a severe disease course, expressed as percent, is given by $[e^A/(1+e^A)]*100$, where e^A is the natural antilogarithm of A and A is calculated as:

$$A = -2.92 + 0.18 * (\text{active joint count}) - 1.23 * (\text{psoriatic arthritis}) - 1.14 * (\text{oligoarthritis}) - 0.49 * (\text{RF-negative polyarthritis}) + 0.75 * (\text{upper limb joint involvement}) - 0.88 * (\text{symmetric joint involvement}) + 1.31 * (\text{RF positivity}) - 1.42 * (\text{subtalar joint involvement}) - 0.31 * (\text{finger joint involvement}) + 0.84 * (\text{cervical spine involvement}) + 0.48 * (\text{ankle joint involvement}) + 0.56 * (\text{presence of morning stiffness}) + 0.06 * (\text{hip involvement}) + 1.50 * (\text{temporal mandibular joint involvement}) + 0.54 * (\text{mid foot involvement}) + 0.86 * (\text{presence of enthesitis})$$





Figure 4. Performance of the best prediction model to predict a severe disease course (severe controlled and severe persisting together). A. Prediction model. B. Model calibration curve. C. Receiver-operating characteristics (ROC) curve. D. Observed frequency of disease courses when the whole cohort is divided into deciles of risk according to the prediction model. The model calibration curve (solid black line in panel B) is a smooth binomial plot. In this plot, the X axis represents the predicted probabilities of a severe disease course made by the model for all patients in the test set and the Y axis is a local average of the observed responses. Along the top and the bottom, we show the patients' observed outcomes, where a 1 indicates a severe course and a 0 indicates otherwise. The vertical dashed bars show the cutoff points at model predictions of about 0.2 and 0.6, which indicate the 3 groupings of low, medium, and high risk. RF: rheumatoid factor.

Cardiovascular Risk Score has c-index values of 0.75–0.80, depending on the cohort^{23,24}.

We considered the overall course of 5 patient-relevant

variables over 5 years, instead of only the number of active joints¹ or the number of cycles of active disease². We chose these variables over the juvenile arthritis core variables

C. ROC Curve for Logistic Regression



D. Patient course by Decile of Logistic Model




Figure 4. Continued.

because we wanted the resulting course groups to reflect the most important issues for patients and parents. We used the Quality of My Life scale as a measure of quality of life, instead of the JAQQ, parent global, or Childhood Health Assessment Questionnaire, because in our previous study

these scales were seen as distinct and the Quality of My Life scale had the most face validity for patients and parents⁶. Our secondary analyses suggest that using the juvenile arthritis core variables may lead to different groups.

We considered many statistical methods and different

groupings of explanatory variables to select the model that best predicted a severe JIA course. We measured performance in data not used for model development to ensure the model had the best predictive ability and did not merely overfit the training data. The selected model (and associated risk calculator) may be a good candidate for the “clinically usable prediction rule” called for by van Dijkhuizen and Wulffraat²⁵.

The Juvenile Arthritis Disease Activity Score 3 (JADAS3), the sum of PGA, parent global assessment, and up to 10 active joints, has been increasingly used in JIA²². JADAS3 varied predictably across the 4 disease courses, but PGA, parent global, or the JADAS3 at enrollment added little predictive value to our prediction model.

It is important to consider 5 possible limitations. First, we excluded many subjects because they attended < 6 study visits. This was a calculated compromise, to include a large enough number of subjects who each had a sufficient followup period (at least 3 yrs). Included subjects were younger (perhaps owing to transferring of adolescents to adult care) and appeared to have a more severe disease at enrollment (perhaps subjects with milder disease missed more study visits). These differences, and the possibility that children with milder JIA may not be referred to a pediatric rheumatologist, suggest that the proportion of children with a severe disease course in the whole JIA population may be less than the reported 20.5%. As is the case in most JIA inception cohorts, the number of subjects with systemic, psoriatic, or rheumatoid factor–positive arthritis was small. It will be interesting to confirm findings in larger groups of children with these JIA categories.

Second, there were substantial missing data requiring imputation; we used a method of imputation that provided values demonstrably close to actual values that had been purposefully deleted, and our sensitivity analyses suggest data imputation was not a source of bias.

Third, it could be argued that using baseline values of a variable to predict a disease course partly defined by changes in that variable over the next 5 years is tautological. On the other hand, it would make no clinical sense to exclude from prediction models variables that are easily ascertained at diagnosis and predict the course. In the final model this potential tautology applied only to the number of active joints.

Fourth, although our medication requirements and side effects scales were assessed in focus groups with patients, parents, and clinicians¹³, they have not been formally validated. Rather than ignoring these important constructs, we chose to use the available scales. We did vary the weighting of scale items in secondary analyses, and it did not substantially change our findings.

Fifth, the described disease courses are inextricably linked to the treatments received by patients in the cohort⁸; different disease courses might have been observed if patients had been treated in a substantially different way.

The implication for practice of our study is that in practical terms, when counseling newly diagnosed families in Canada, a physician may describe the 4 JIA disease courses and give a reasonable estimate of the chance that the child will follow a severe course. This information can then be considered alongside the inconveniences and possible side effects of treatment to help arrive at a well-informed shared decision. Better knowledge of what to expect from the disease may decrease the uncertainty and anxiety of parents facing a diagnosis of JIA in their child. The implication for research is that because our cohort was similar to cohorts in other Western countries, our results may apply to children in those countries, but this will require confirmation in a local cohort. It will be important to apply our analysis methods to other JIA cohorts to understand differences across settings. Given the importance that families place on medication requirements and side effects, there is a need to validate scales for assessing them.

Based on changes over 5 years in 5 variables chosen by patients, parents, and clinicians, children with JIA in the ReACCh-Out cohort were grouped into 4 clinical courses. Most children followed a mild or a moderate course, but a minority followed 1 of 2 severe courses. One was controlled with treatment despite very high initial active joint counts, and 1 had a protracted effect on quality of life and pain, despite intensive treatment and moderately decreasing joint counts. A prediction model that combined JIA category and active joint count with other features usually known at diagnosis was able to estimate the risk of a severe JIA course in each patient with accuracy similar to methods for predicting cardiovascular disease used in current practice guidelines.

APPENDIX 1.

List of study collaborators. The ReACCh-Out Investigators. Here follow the additional investigators in the Research in Arthritis in Canadian Children emphasizing Outcomes Study: Roxana Bolaria, Katherine Gross, Stuart E. Turvey, David Cabral, Kristin Houghton, Kimberly Morishita, Ross Petty, University of British Columbia; Janet Ellsworth, the Stollery Children's Hospital and University of Alberta, Edmonton; Nicole Johnson, Paivi Miettunen, Heinrike Schmeling, the Alberta Children's Hospital and University of Calgary, Calgary; Alan M. Rosenberg, Royal University Hospital and University of Saskatchewan, Saskatoon; Kiem Oen, Winnipeg Children's Hospital and University of Manitoba, Winnipeg; Maggie Larché, McMaster University, Hamilton, Ontario; Brian M. Feldman, Deborah M. Levy, Ronald M. Laxer, Debbie Feldman, Lynn Spiegel, Rayfel Schneider, Shirley M.L. Tse, Earl Silverman, Bonnie Cameron, Rae S.M. Yeung, Hospital for Sick Children and University of Toronto, Toronto, Ontario; Johannes Roth, Michele Gibbon, Karen Watanabe Duffy, Ciarán M. Duffy, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario; Anne-Laure Chetaille, Jean Dorval, Centre Hospitalier Universitaire de Laval and Université Laval, Quebec City; Gilles Boire, Alessandra Bruns, Centre Hospitalier Universitaire de Sherbrooke and Université de Sherbrooke, Sherbrooke; Rosie Scuccimarri, Sarah Campillo, Gaëlle Chédeville, Claire LeBlanc, McGill University Health Centre and McGill University, Montreal; Elie Haddad, Claire St. Cyr, CHU Ste. Justine and Université de Montréal, Montréal, Quebec; Bianca Lang, Suzanne E. Ramsey, Elizabeth Stringer, Adam M. Huber, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; Paul Dancey, Janeway Children's Health and Rehabilitation Centre and Memorial University, Saint John's, Newfoundland, Canada.

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

REFERENCES

1. Berard RA, Tomlinson G, Li X, Oen K, Rosenberg AM, Feldman BM, et al. Description of active joint count trajectories in juvenile idiopathic arthritis. *J Rheumatol* 2014;41:2466-73.
2. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. *Arthritis Rheum* 2005;52:3554-62.
3. Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. *Best Pract Res Clin Rheumatol* 2002;16:347-60.
4. Ravelli A, Martini A. Early predictors of outcome in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2003;21 Suppl 31:S89-93.
5. Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis: II. predictors of outcome in juvenile arthritis. *Rheumatology* 2005;44:1002-7.
6. Guzman J, Gómez-Ramírez O, Jurencak R, Shiff N, Berard R, Duffy C, et al. What matters most for patients, parents, and clinicians in the course of juvenile idiopathic arthritis? A qualitative study. *J Rheumatol* 2014;41:2260-9.
7. Oen K, Tucker L, Huber AM, Miettunen P, Scuccimarri R, Campillo S, et al. Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study. *Arthritis Rheum* 2009;61:1077-86.
8. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al for the ReACCh-Out Investigators. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. *Ann Rheum Dis* 2015;74:1854-60.
9. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. *Arthritis Rheum* 1997;40:1202-9.
10. Duffy CM, Arsenault L, Duffy KN, Paquin JD, Strawczynski H. The Juvenile Arthritis Quality of Life Questionnaire—development of a new responsive index for juvenile rheumatoid arthritis and juvenile spondyloarthritis. *J Rheumatol* 1997;24:738-46.
11. Feldman BM, Grundland B, McCullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. *J Rheumatol* 2000; 27:226-33.
12. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol* 2004;31:390-2.
13. Tucker LB, Shiff N, Benseler S, Berard R, Jurencak R, Loughin T, et al. Scoring medication requirements and side-effects in juvenile idiopathic arthritis: perspectives of patients, parents and clinicians [abstract]. *Arthritis Rheumatol* 2015;67 Suppl 10:2451.
14. Schafer JL. Multiple imputation: a primer. *Stat Methods Med Res* 1999;8:3-15.
15. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. *J Clin Epidemiol* 2003;56:968-76.
16. Genolini C, Écochard R, Jacqmin-Gadda H. Copy mean: a new method to impute intermittent missing values in longitudinal studies. *Open J Stat* 2013;3:26-40.
17. Genolini C, Pingault JB, Driss T, Côté S, Tremblay RE, Vitaro F, et al. KmL3D: a non-parametric algorithm for clustering joint trajectories. *Comput Methods Programs Biomed* 2013;109:104-11.
18. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference, and prediction. 2nd ed. New York: Springer; 2009.
19. Izenman AJ. Modern multivariate statistical techniques: regression, classification, and manifold learning. New York: Springer; 2008.
20. Hubert L, Arabie P. Comparing partitions. *J Classif* 1985;2:193-218.
21. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. *Arthritis Rheum* 1994;37:1761-9.
22. McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al; Childhood Arthritis Prospective Study (CAPS). Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. *Ann Rheum Dis* 2013;72:1983-8.
23. Cui J. Overview of risk prediction models in cardiovascular disease research. *Ann Epidemiol* 2009;19:711-7.
24. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. *Circulation* 2010;121:1768-77.
25. van Dijkhuizen EH, Wulffraat NM. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. *Ann Rheum Dis* 2015;74:1996-2005.